Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
Not yet recruiting · NCT07011589 · Registry updated 2026-05-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) | Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, acquired epidermolysis bullosa, connective tissue disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, hereditary disease, hereditary skin disorder, recessive dystrophic epidermolysis bullosa, skin disorder, vesiculobullous skin disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-05 | NCT07011589 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| argenx | 52 |
| M. Peter Marinkovich | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Stanford University | Redwood City | United States | 2 |